2000
HTLV-II and Bacterial Infections Among Injection Drug Users
Safaeian M, Wilson L, Taylor E, Thomas D, Vlahov D. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 483-487. DOI: 10.1097/00126334-200008150-00012.Peer-Reviewed Original ResearchHTLV-II infectionInjection drug usersHTLV-IIBacterial pneumoniaInfective endocarditisOdds ratioBacterial infectionsDrug usersChart reviewConditional logistic regression methodsSelf-reported skinStandardized chart reviewOngoing cohort studyCase-control studyEnzyme-linked immunosorbentCohort studyHIV statusSkin abscessesRisk factorsControl studyEndocarditisInfectionImmunofluorescent assayPneumoniaLogistic regression methodHTLV-II and Bacterial Infections Among Injection Drug Users
Safaeian M, Wilson L, Taylor E, Thomas D, Vlahov D. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 483-487. DOI: 10.1097/00042560-200008150-00014.Peer-Reviewed Original ResearchConceptsHTLV-II infectionInjection drug usersHTLV-IIBacterial pneumoniaInfective endocarditisOdds ratioBacterial infectionsDrug usersChart reviewConditional logistic regression methodsSelf-reported skinStandardized chart reviewOngoing cohort studyCase-control studyEnzyme-linked immunosorbentCohort studyHIV statusResults PrevalenceSkin abscessesRisk factorsControl studyEndocarditisInfectionImmunofluorescent assayPneumonia
1996
An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users
Hershow R, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein R, Jarlais D, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, Kaplan J. An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users. The Journal Of Infectious Diseases 1996, 174: 309-317. PMID: 8699060, DOI: 10.1093/infdis/174.2.309.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell percentCell percentHuman immunodeficiency virus type 1 (HIV-1) disease progressionHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersInfected injection drug usersVirus type 1 infectionHuman T-lymphotropic virus type IIHIV seroconversion datesHTLV-II infectionType 1 infectionProportional hazards modelEffect of coinfectionSeroconversion datesCohort studyHIV infectionHTLV infectionDisease progressionAIDS mortalityHTLV-IIHazards modelRate of declineInternational collaborative studyWestern blot
1991
Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.
Viscidi R, Hill P, Li S, Cerny E, Vlahov D, Farzadegan H, Halsey N, Kelen G, Quinn T. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 1190-8. PMID: 1941526.Peer-Reviewed Original ResearchConceptsEnzyme immunoassayHTLV-IIAntibody reactivityPeptide enzyme immunoassayHTLV-II infectionEpidemiology of HTLVDifferentiation of HTLVMicrotiter plate enzyme immunoassaysPattern of reactivitySeronegative controlsEmergency departmentEnv peptidesPositive seraViral infectionNeurological diseasesHTLVSynthetic peptidesInfectionDrug abuseMajor envelope proteinEnvEnvelope proteinPatientsSerumAntibodies